Literature DB >> 18412170

Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis.

Xin Zhang1, Yunan Tang, Danuta Sujkowska, Jinzhao Wang, Vinod Ramgolam, Mireia Sospedra, Jeremy Adams, Roland Martin, Clemencia Pinilla, Silva Markovic-Plese.   

Abstract

TCR degeneracy may facilitate self-reactive T cell activation and the initiation of an autoimmune response in multiple sclerosis (MS). MHC class II alleles of the DR2 haplotype DR2a (DRB5*0101) and DR2b (DRB1*1501) are associated with an increased risk for MS in Caucasian populations. In order to selectively expand and characterize T cells with a high degree of TCR degeneracy that recognize peptides in the context of disease-associated DR2 alleles, we developed DR2-anchored peptide mixtures (APM). We report here that DR2-APM have a high stimulatory potency and can selectively expand T cells with a degenerate TCR (TCR(deg)). Due to the low concentration of individual peptides in the mixtures, T cell clones' proliferative response to DR2-APM implies that multiple peptides stimulate the TCR, which is a characteristic of TCR(deg). The frequency of DR2-APM-reactive T cells is significantly higher in MS patients than in healthy controls, suggesting that they may play a role in the development of the autoimmune response in MS. DR2-APM-reactive cells have a dual DR2 restriction: they recognize DR2-APM in the context of both DR2a and DR2b molecules. The DR2-APM-reactive cells' IL-17 secretion, together with cross-reactivity against myelin peptides, may contribute to their role in the development of autoimmune response in MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18412170     DOI: 10.1002/eji.200737519

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys.

Authors:  LaKisha K Buie; Carol A Rasmussen; Eric C Porterfield; Vinod S Ramgolam; Vivian W Choi; Silva Markovic-Plese; Richard J Samulski; Paul L Kaufman; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-13       Impact factor: 4.799

Review 2.  Autoimmune T cell responses in the central nervous system.

Authors:  Joan Goverman
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

Review 3.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

Review 4.  Multiple sclerosis and regulatory T cells.

Authors:  Cristina Maria Costantino; Clare Baecher-Allan; David A Hafler
Journal:  J Clin Immunol       Date:  2008-09-02       Impact factor: 8.317

Review 5.  The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?

Authors:  Benedetta Parodi; Nicole Kerlero de Rosbo
Journal:  Front Immunol       Date:  2021-09-21       Impact factor: 7.561

6.  Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.

Authors:  Monika Tschochner; Shay Leary; Don Cooper; Kaija Strautins; Abha Chopra; Hayley Clark; Linda Choo; David Dunn; Ian James; William M Carroll; Allan G Kermode; David Nolan
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

Review 7.  Involvement of CD8(+) T Cells in Multiple Sclerosis.

Authors:  Marion Salou; Bryan Nicol; Alexandra Garcia; David-Axel Laplaud
Journal:  Front Immunol       Date:  2015-11-26       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.